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Abbreviations:  
ALS   amyotrophic lateral sclerosis 
CNS   central nervous system 
CSF   cerebrospinal fluid 
EAE   experimental autoimmune encephalomyelitis 
ELISA   enzyme-linked immunosorbent assay 
hIgG   human immunoglobulin G 
mAb   monoclonal antibody 
MOG   myelin oligodendrocyte glycoprotein 
MS   multiple sclerosis 
NF-L   neurofilament light 
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rmNF-L   recombinant mouse NF-L 
RGC   retinal ganglion cells 
RNFL   retinal nerve fiber layer 
pwMS   people with multiple sclerosis 
 
Summary 
Antibodies to neuronal antigens are associated with many neurological diseases 
including paraneoplastic neurological disorders, epilepsy, amyotrophic lateral sclerosis 
and multiple sclerosis. Immunisation with neuronal antigens such as neurofilament light 
NF-L, a neuronal intermediate filament in axons, has been shown to induce 
neurological disease and spasticity in mice. Also, while antibodies to NF-L are widely 
used as surrogate biomarkers of axonal injury in amyotrophic lateral sclerosis and 
multiple sclerosis, it remains to be elucidated if antibodies to NF-L contribute to 
neurodegeneration and neurological disease. To address this, we examined the 
pathogenic role of antibodies directed to NF-L in vitro using spinal cord co-cultures and 
in vivo in experimental autoimmune encephalomyelitis (EAE) and optic neuritis animal 
models of multiple sclerosis. Here we show that peripheral injections of antibodies to 
NF-L augmented clinical signs of neurological disease in acute EAE, increased retinal 
ganglion cell loss in experimental optic neuritis and induced neurological signs 
following intracerebral injection into control mice. The pathogenicity of antibodies to 
NF-L was also observed in spinal cord co-cultures where axonal loss was induced. 
Taken together, our results reveal that as well as acting as reliable biomarkers of 
neuronal damage, antibodies to NF-L exacerbate neurological disease, suggesting that 
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antibodies to NF-L generated during disease may also be pathogenic and play a role in 
the progression of neurodegeneration.  
 
Introduction 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) that has a strong neurodegenerative component[1]. While 
several studies show that current therapies targeting the adaptive immune pathways 
are effective in people with MS (pwMS) with active inflammatory lesions, such 
approaches fail to show efficacy in progressive disease associated with irreversible 
axonal damage and neuronal loss. However, both B and T cells and immunoglobulin 
deposits are present in the CNS in primary and secondary progressive MS irrespective 
of the disease duration[2], indicating that immune responses may continue to play a 
role in progressive disease.  
Although the aetiology of MS is still unclear, T cells and immunoglobulins (Ig) directed 
to myelin and axonal proteins as well as myelin associated antigens such as the heat 
shock protein HSPB5 are present in peripheral blood and the cerebrospinal fluid (CSF) 
in pwMS[3-7], though some studies also show that these are also present in healthy 
controls[7-9]. A clear role for immune responses in MS is evidenced by the efficacy of 
immunotherapy as a treatment strategy[10]. Additional evidence comes from the 
similarities between experimental autoimmune encephalomyelitis (EAE) and MS. In 
EAE, autoimmune responses to myelin proteins and peptides[11-13] as well as spinal 
cord homogenates[14] induce chronic relapsing neurological disease and 
demyelination that is enhanced in the presence of demyelinating antibodies[15, 16].  
In the CSF of pwMS, the presence of intrathecal oligoclonal antibody production has 
led to a search for the specificity of these antibodies based on the concept that they are 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
involved in the pathogenesis of MS. Some of these antibodies are directed to the 
neuronal cytoskeleton protein neurofilament light (NF-L) and are increased in the 
CSF[17] and serum[18] in progressive MS. Likewise, CNS resident B cells have shown 
characteristics of an antigen driven response, including specificity to NF-L[19].  
However, the question arises whether antibodies to CNS antigens such as NF-L are 
pathogenic. Previously, we have shown that mice immunized with NF-L develop 
neurological disease characterized by spasticity and limb paralysis associated with 
axonal degeneration and inflammation in the dorsal column and the grey matter[8, 20, 
21]. Furthermore, in these mice immunoglobulin is observed inside axons of mice 
immunized with NF-L which develop neurological disease[8]. This finding is in line with 
the observations that neuronal intracellular antigens are targets of specific humoral 
immune responses[22-26]. However, in the NF-L induced spasticity it was unclear 
whether the antibodies directed to NF-L are themselves responsible for the 
pathogenicity in this model. In humans, it has recently been shown that IgG and IgM 
localize with neurofilaments in MS lesions[27]. Nonetheless, the contribution of 
antibodies to NF-L in MS remains unclear.  
Here, we examined the pathogenic effect of antibodies directed to NF-L in vitro using 
spinal cord co-cultures and in vivo in mice. We show that a monoclonal antibody (mAb) 
to NF-L induced axonopathy in rat dissociated spinal cord co-cultures, promoted 
neurodegeneration in a mouse model of optic neuritis, exacerbated active EAE in mice 
and induced neurological signs after intracerebral injection in naive mice. Taken 
together, our results indicate a pathogenic role of antibodies to neuronal antigens and 
show that antibodies to NF-L exacerbate neuronal damage in experimental disease. 
These findings indicate that NF-L antibodies might also contribute to 
neurodegeneration in MS. 
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Materials and methods 
Animals 
Mice: For EAE studies Biozzi ABH (H-2dq1) female and male mice between 8-10 weeks 
old were obtained from Harlan Ltd (UK) or bred at Queen Mary University of London 
(UK). For optical coherence tomography and retinal ganglion cell (RGC) analysis, 10 
weeks old female and male transgenic C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch.Cg-
Tg(Thy1-CFP)23Jrs/J mice expressing T cell receptors specific for myelin 
oligodendrocyte glycoprotein (MOG) and RGC expressing cyan fluorescent protein 
(CFP) were used (about 25% of the offspring)[28]. Animals were housed in a 
temperature-controlled room (25°C) and given access to food and water ad libitum[29]. 
All procedures were performed following institutional ethical review in accordance to 
the United Kingdom Animals (Scientific Procedures) Act (1986) and European Union 
Directive 2010/63/EU and the German Review Board for the Care of Animal Subjects 
of the district government (North Rhine-Westphalia, Germany) under the 
recommendations of the Federation of European Laboratory Animal Science 
Associations. Further details relating to animal husbandry and operational experimental 
design relating to the ARRIVE guidelines reporting have been described previously[29].  
Rats: Time-mated Sprague-Dawley rats[30, 31] purchased from Charles River 
(Germany) were housed in a temperature-controlled room and given access to food 
and water ad libitum. All experimental procedures were reviewed and approved by the 
Ethical Committee for Animal Experiments of the VU Medical Centre, Amsterdam, The 
Netherlands (PA 13-01). 
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Human Subjects  
People with relapsing-remitting MS (RRMS) were recruited at The Royal London 
Hospital, London, UK and La Fe Polytechnic and University Hospital in Valencia, 
Spain. People with secondary progressive MS (SPMS) were recruited from the 
National Hospital for Neurology and Neurosurgery, London, and the Royal Free 
Hospital, London, UK (Supplementary Table 1). Sera were obtained with informed 
consent from the donors. All procedures were approved by the local ethical 
committees. Ethical approval was obtained from the North London REC 2 
(10/H0724/36), Hospital Universitario La Fe Committee, University College London 
Hospitals Committee and National Research Ethics Committee (REC:06/Q0512/16, 
EudraCT: 2005-005588-27). All studies were carried out in accordance with The Code 
of Ethics of the World Medical Association (Declaration of Helsinki).  
 
Antibodies 
The mouse monoclonal antibody to NF-L used in the current study, NF-L 10H9, has 
been described in a previous study[4]. The affinity purified anti-human NF-L rabbit 
polyclonal antibody was obtained from (Abbexa, Cambridge, UK). Total human IgG 
preparations were purified from serum of either pwMS that showed high reactivity to 
NF-L protein in an enzyme-linked immunosorbent assay (ELISA, Supplementary Table 
1) or healthy controls. Pooled IgG fractions were diluted 1:10 in phosphate buffered 
saline (PBS) and purified using a 1 ml HiTrap protein-G HP column (GE Healthcare). 
IgG bound to the column was eluted with 0.1 M citric acid (pH 3.0) and neutralized with 
1 M Tris-HCl (pH 9.1). Samples were concentrated using Amicon® Ultra centrifugal 
filters (UFC501096, Millipore, UK) and the buffer was exchanged for PBS. The IgG 
concentration was measured using a NanoDrop ND-1000 Spectrophotometer.  
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Western blotting 
Western blotting was carried out to show the reactivity of NF-L 10H94 and purified hIgG 
to spinal cord, brain homogenates and recombinant NF-L. Serum from NF-L 
immunized ABH mice32 was used as a positive control. Briefly, 0.49 mg/ ml 
recombinant mouse NF-L (rmNF-L), or 10 μg mouse spinal cord or brain homogenate 
were separated using Mini-Protean TGX Precast Gel (Bio-Rad, Germany) and 
transferred onto Whatmann nitrocellulose membranes. The nitrocellulose membranes 
were blocked with 5% fat-free milk solution and 0.5% bovine serum albumin for 1 h. 
Membranes were incubated with NF-L 10H9 (10 µg/ml) or hIgG (50 µg/ml) overnight. 
After washing, goat anti-mouse IgG-horseradish peroxidase (Dako, Denmark) was 
added to the membranes and incubated for 1 h at room temperature. Visualization was 
performed with the chromogen 3,3’-diaminobenzidine (Dako) and enhanced 
chemiluminescence (Amersham, UK). 
 
Induction of EAE and administration of NF-L antibodies 
ABH mice were injected subcutaneously with 200 μg MOG35-55 peptide emulsified with 
incomplete Freund’s adjuvant (Difco Laboratories, UK) supplemented with 48 μg 
Mycobacterium tuberculosis and 6 μg M. butyricum (Difco Laboratories) on day 0 and 
7, as described previously[11, 29]. Mice were also injected intraperitoneally with 200 ng 
of Bordetella pertussis toxin (Sigma, UK) immediately after the immunisation and at 24 
h and 8 d after immunisation. Mice were intraperitoneally injected with 0.5 mg NF-L 
10H9 or 0.5 mg hIgG from day 10 every other day until day 26. Mice were monitored 
daily and scored according to a neurological scale with 0 = normal, 1 = limp tail, 2 = 
impaired righting reflex, 3 = hindlimb paresis and 4 = hindlimb paralysis[8, 32]. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Induction of optic neuritis 
Transgenic mice were used to study whether NF-L 10H9 induced loss of RGC as 
described previously with anti-myelin antibodies[28]. Optic neuritis was induced in 
MOG-specific T cell receptor transgenic mice with fluorescent RGC by injection with 
150 ng B. pertussis toxin (Sigma) on day 0 and day 2[28]. Subsequently, mice were 
randomly divided into two groups. One group (Group A) was injected with 0.5 mg 
fluorescently labeled NF-L 10H9-PE (phycoerythrin) on days 11, 12 and 13 and 
euthanized on day 15. The other group (Group B) was injected with 0.5 mg mAb 
unlabeled NF-L 10H9 on days 14, 16 and 18 and euthanized at day 20. As a negative 
control mice were injected with isotype control IgG1 (Sigma). Optical coherence 
tomography was used to measure changes in the retinal nerve fiber layer (RNFL) 
thickness comparing measurements before  B. pertussis toxin injection (day 0) and 
after injection of antibodies to NF-L (days 15 and 20)[28]. Retinal flat-mounts were 
prepared for fluorescent microscopy and RGC density was calculated as described 
previously[28]. 
 
Intracerebral administration of NF-L antibodies 
Intracerebral injection of NF-L 10H9, mAb MOG Z12[33] and hIgG was performed in 
female ABH mice anesthetized by inhalation with isoflurane. Briefly, 30 µg of NF-L 
10H9, mAb MOG Z12 and 180 µg hIgG from pwMS or healthy controls was 
administered intracerebrally to the forebrain of mice[34]. 
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PC12 cell viability 
Undifferentiated PC12 cells were cultured in DMEM (Invitrogen, UK) supplemented 
with 10% FCS (Invitrogen) and 10% horse serum (Sigma, UK), 100 μg/ml streptomycin, 
100 U/ml penicillin (Invitrogen) and incubated at 37°C with 5% CO2 humidified 
atmosphere. The cells  were  differentiated by plating at a density of 1×105 in 96 well 
plates (Nunc, Thermofisher, UK) in DMEM medium with 0.1% horse serum 
supplemented with NGF (50 ng/ml). After 48 h, the differentiated PC12 cells were 
treated for 24 h, 48 h or 72 h with 20 μg/ml of either rabbit IgG directed to human NF-L 
(Abbexa), rabbit IgG as control (Sigma) or medium only. The cell viability was 
determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. For analysis the treated cells were incubated with MTT (0.5 mg/ml) 
during the final 4 h of incubation, the supernatants were discarded and 200 μL dimethyl 
sulfoxide was added to solubilise the formazan crystals. The absorbance was 
determined at 590 nm using an ELISA reader (ELISA, Synergy HT microplate reader). 
The percentage of cell viability was calculated as the absorbance of experimental 
group/ absorbance of control (media only). 
 
Axonal density in myelinating spinal cord cultures 
Myelinating co-cultures were prepared as described previously[30, 31]. Briefly, spinal 
cords were dissected from E15 rat pups and enzymatically dissociated. Cells were 
plated on a confluent monolayer of neurosphere derived astrocytes[30] and allowed to 
develop to form a co-culture containing axons, glia and the various cell types that make 
up the spinal cord for their detailed study. After 23-24 days, the co-cultures were 
treated with the monoclonal antibody to NF-L. Spinal cord co-cultures were incubated 
with 10 μg/ml NF-L 10H9 or the isotype control (mouse IgG1, Sigma) for 0.5 h to 48 h 
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at 37°C in the presence of 5% CO2 in duplicate as described previously[35]. Cultures 
were stained for phosphorylated axons/neurites with unlabeled anti-mouse SMI310 
IgG1 and goat-anti mouse- Alexa Fluor-594 F(ab')2 fragment was used as secondary 
antibody (1:1500; Abcam, UK). Cells were imaged on a Leica DMR fluorescence 
microscope using a Leica DFC4000 camera. Briefly, 20 images were analyzed per 
condition using ImageJ software (NIH systems, version 1.41o). For each time point, 
three independent myelinating co-cultures were used and per condition the images 
were analyzed (10 per coverslip, 2 coverslips per condition). The number of pixels of 
SMI310+ neurites were measured and divided by the total number of pixels per field of 
view, resulting in the percentage of axonal density. Subsequently, for each time point, 
the percentage of axonal density from NF-L 10H9 treated co-cultures was calculated in 
relation to the isotype control IgG1 treated co-cultures, resulting in the percentage of 
axonal loss.  
 
Statistics 
Data were analyzed using GraphPad Prism (5.01) and expressed as means ± standard 
error of the mean (SEM) unless otherwise specified. RNFL thinning and RGC density 
were analyzed using Student’s t-test. Statistical analysis of clinical scores was 
assessed using the non-parametric Mann-Whitney U test. Axonal density of rat spinal 
cord co-cultures was quantified with ImageJ and analyzed with GraphPad Prism (5.01) 
using the Student’s t-test with. P values of less than 0.05 were considered statistically 
significant.  
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Results 
Specificity of mAb to NF-L  
The specificity of NF-L clone 10H9 was verified in western blot analysis using mouse 
spinal cord, brain homogenate and recombinant NF-L protein (Fig. 1). Similarly, hIgG 
purified from selected pwMS with high levels of NF-L antibodies, showed reactivity 
mainly to a protein at the molecular weight of the linear NF-L protein (68 kDa) 
(Supplementary Figure 1). 
 
Antibodies to NF-L exacerbates MOG35-55 induced EAE 
To examine the in vivo pathogenic effect of NF-L 10H9 antibody, mice were immunized 
with MOG35-55 (n=11) and injected i.p. with NF-L 10H9 (n=6) every other day from 10 d 
post-immunisation. The cumulative EAE score in mice immunized with MOG35-55 and 
injected with NF-L 10H9 was significantly increased compared to control EAE mice 
(p=0.01; Table 2). Likewise, injection of serum IgG from pwMS results in an early onset 
of clinical signs of disease compared to untreated mice (11.8 ± 1.0 days versus 14.1 ± 
2.1 days; *p<0.05) (Supplementary Figure 2). 
 
RGC density is significantly affected by antibodies to NF-L 
Since the majority of people with MS develop ocular deficits, we investigated whether 
the NF-L 10H9 antibodies were pathogenic to RGCs. Damage to the RGC can occur 
as a downstream consequence of damage to the optic nerve during optic neuritis[36]. 
Delivery of fluorescently labeled NF-L 10H9-PE after the onset of optic neuritis caused 
a significant reduction in the mean RGC density at 20 days post-induction (group B), 
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compared to mice injected with the isotype IgG1 control (p<0.05). This effect was not 
apparent at 15 days (Fig. 2A, group A). NF-L 10H9 had no significant effect on the 
thickness of the RNFL in mice with optic neuritis (Fig. 2B).  
  
Intracerebral injection of antibodies to NF-L causes transient neurological signs 
To further investigate the pathogenicity of antibodies to NF-L, NF-L 10H9 was injected 
intracerebrally into naive ABH mice. Significant neurological symptoms were apparent 
after recovery from the anaesthetic (Supplementary Figure 3A and B). This effect was 
also observed following injection of hIgG from pwMS (Supplementary Figure 3C). The 
neurological signs included stiffness of hind limbs, tail stiffness, paresis of the hind 
limbs and subsequent movement abnormalities. In contrast, mice injected with mouse 
serum, mAb MOG Z12 or saline solution did not develop signs of disease.   
 
Antibodies to NF-L decrease neuronal viability 
The pathogenic effect of antibodies to NF-L was examined using the PC12 cell line. No 
effect of the control rabbit Ig was observed over the study. In contrast a neurotoxic 
effect of NF-L antibody was observed within 24 h that decreased the cell viability 
compared to control rabbit IgG (p < 0.01) and media only (p < 0.001) (Fig. 3).  This was 
mirrored at 48 and 72h. By contrast, the control IgG antibody had no significant effect 
on cell viability.  
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Pathogenic effect of mAb to NF-L in spinal cord cultures 
To further examine the in vivo effect of NF-L antibodies the antibody 10H9 was applied 
to rat spinal cord co-cultures and the density of phosphorylated axons and neurites 
used as a measure of axonal damage as described previously[31, 35, 37]. The 
monoclonal NF-L 10H9 induced axonal loss in the culture system relative to the isotype 
control IgG1 (Fig. 4A); n =3-4; p<0.05). After 1 h incubation with NF-L 10H9, axonal 
loss was significantly increased compared to isotype control treated cultures (p<0.001; 
Fig. 4A). Representative immunofluorescent images of cultures incubated with isotype 
control IgG1 (Fig. 4B) and NF-L 10H9 (Fig. 4C) reveal significant loss of the axonal 
network. 
 
Discussion 
Antibodies to NF-L have been previously evaluated as surrogate biomarkers of 
neuronal damage. We show, for the first time, that antibodies to neurofilaments 
contribute to neuronal damage. Our data indicate that antibodies to NF-L might be 
involved in disease progression in neurodegenerative diseases such as MS and other 
neurodegenerative diseases in which antibodies to NF-L have been reported[17, 18, 
38]. Thus, therapeutic approaches targeting humoral immunity to neurons and axons 
could be beneficial in a variety of neurological disorders. There is some evidence of the 
efficacy of this approach already. In MS therapeutic strategies targeting B cells reduce 
disease severity[39, 40] although such efficacy might not be due to a direct effect of 
reducing autoantibodies. In general, subgroups of pwMS respond well to plasma 
exchange[41-43], indicating that pathogenic antibodies contribute to disease.  
Although pwMS experience various symptoms, visual problems commonly precede 
other neurological symptoms. Optical coherence tomography can be used to assess 
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damage to the retina. Here, we used a new optic neuritis model[28] to investigate 
whether mAb to NF-L have a pathogenic effect on RNFL thickness and RGC density 
consequent to damage of axons within the optic nerve. Similar to effects noted with 
injection of mAb to MOG[28], injection of NF-L 10H9 into animals with optic neuritis 
significantly reduced RGC density 20 days post-injection. The significance of 
antibodies to NF-L in pwMS who develop optic neuritis has not been accounted before 
and deserves further investigation. 
Here we also show early onset of disease and exacerbation of MOG35-55-induced EAE, 
following injection of IgG purified from sera of multiple pwMS with high levels of NF-L 
antibodies (Supplementary Figure 1), and a significant increase in the cumulative score 
induced following injection with the mAb NF-L. This suggests that antibodies to 
neuronal antigens, such as those to NF-L, may elicit an additional reaction causing 
neuronal damage. The differential effect observed on the EAE course after injection of 
the mAb NF-L or hIgG could be due to differences in specificity and therefore 
pathogenicity of these antibodies in pwMS compared to the mouse monoclonal. This is 
in line with previous studies by Pedotti et al[16] showing that IgG purified from plasma 
from a RRMS patient exacerbated PLP-induced EAE in mice. Absorption and affinity 
studies are required to identify the contribution of the NF-L antibodies as well as other 
antibodies present in the purified human IgGs. Nevertheless, we have previously 
shown that autoimmune T cell responses to neuronal antigens augment experimental 
autoimmune disease[32] while other reports show that antibodies to neurofascin 
augments neuronal damage[3] underscoring the potential importance of autoimmunity 
to neurons in humans.  
To overcome the influence of the blood-brain barrier in the penetration of antibodies 
into the CNS, mAb were injected intracerebrally in mice. These antibodies induced the 
development of MS-like symptoms, including ataxia, spasticity and paralysis. Some 
studies have shown that antibodies to an intracellular antigen have the ability to enter 
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neurons causing depletion of adenosine triphosphate and increase of caspase levels 
that could lead to apoptosis and cell death[44]. This mechanism together with an 
elevation in intracellular Ca2+ mediated by anti-alpha-enolase antibodies has also been 
described in autoimmune retinopathy[45]. In addition, activation of FcγRI by IgG-
immune complex has been shown to cause an increase in intracellular calcium and 
enhance excitability in sensory neurons[46]. Patch-clamping might be used to 
investigate whether mAb to NF-L impact on neuronal signaling. Our data also show 
that both NF-L specific and isotype antibodies can be internalized by neurons (data not 
shown). Once internalized, antibodies to NF-L might disturb axonal transport processes 
by binding to their target. Here we show that an anti-human NF-L antibody decreased 
remarkably the viability of differentiated neurons as measured in an MTT assay that 
reflects the amount of mitochondrial activity. We also show that mAb to NF-L reduced 
axonal density in rat spinal cord co-cultures which might be the consequence of failure 
of proper axonal transportation. The ability of antibodies directed to intracellular 
neuronal targets to disrupt axonal transport has been shown before[47, 48].  
Further research needs to be performed to determine the mechanism by which 
antibodies to NF-L cause cytotoxicity. It is also possible that antibody-antigen 
complexes of neurofilament proteins and antibodies crosslink with Fc-receptors on 
immune cells which can trigger phagocytosis, antibody-dependent cell-mediated 
cytotoxicity and cytokine release[49] thereby contributing to progression in 
neuroinflammatory conditions.  
Our previous studies show that antibodies to NF-L are diminished in response to 
disease modifying therapies in MS[50] and are also correlated with fast progression of 
ALS[38], which further suggest a pathogenic role of these antibodies. In this study, we 
expand some of our previous observations of the presence of Ig deposits within axons 
in lesions of mice exhibiting clinical disease[8]. Our results show that antibodies to 
intracellular antigens contribute to axonal damage and are not just surrogate markers 
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of disease. This may open novel potential therapeutic targets for antibodies interfering 
with these responses. 
 
Acknowledgments 
We thank Wouter Gerritsen for his exceptional technical skills and Kamilla Nurtaeva 
and Adib Zendedel for excellent technical assistance with stereotactic injections. PC12 
cells were kindly provided by Dr. Alexandra Chittka. We also thank Katie Lidster for 
technical assistance on optic neuritis studies. This work was supported by Stichting MS 
Research, The Netherlands (grant number 07–627), the DANA foundation and by the 
MS Society of the United Kingdom (grant number NSCG-1F7R). 
 
Disclosures 
The authors declare that there are no conflicts of interest. 
 
Contribution of authors 
FP, BJS, SA, contributed to the conception and design of the study. FP, BJS, SB, MK, 
LB, JS, SCB, performed the experiments. IB, JR, SG, provided the samples from MS 
patients. FP, BJS, SB, MK, LB, IB, JS, JR, SG, PV, SCB, DB and SA contributed to the 
interpretation of the results, writing and revision of the manuscript. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
References 
1. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative 
disorder? Annu Rev Neurosci 2008;31:247-69. 
2. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, 
Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between 
inflammation and neurodegeneration in multiple sclerosis brains. Brain 
2009;132:1175-89. 
3. Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, Krumbholz M, Kumpfel T, 
Moldenhauer A, Rader C, Sonderegger P, Pollmann W, Tiefenthaller C, Bauer J, 
Lassmann H, Wekerle H, Karagogeos D, Hohlfeld R, Linington C, Meinl E. Contactin-
2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates 
gray matter pathology in animals. Proc Natl Acad Sci U S A 2009;106:8302-7. 
4. Huizinga R, van der Star BJ, Kipp M, Jong R, Gerritsen W, Clarner T, Puentes 
F, Dijkstra CD, van der Valk P, Amor S. Phagocytosis of neuronal debris by microglia 
is associated with neuronal damage in multiple sclerosis. Glia 2012;60:422-31. 
5. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-
Hayani A, Davies SN, Rasband MN, Olsson T, Moldenhauer A, Velhin S, Hohlfeld R, 
Meinl E, Linington C. Neurofascin as a novel target for autoantibody-mediated axonal 
injury. J Exp Med 2007;204:2363-72. 
6. Thompson EJ, Kaufmann P, Shortman RC, Rudge P, McDonald WI. Oligoclonal 
immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis. Br 
Med J 1979;1:16-7. 
7. Van Noort JM, Van Sechel AC, Bajramovic JJ, El Ouagmiri M, Polman CH, 
Lassmann H, Ravid R. The small heat-shock protein alpha B-crystallin as candidate 
autoantigen in multiple sclerosis. Nature 1995;375:798-801. 
8. Huizinga R, Heijmans N, Schubert P, Gschmeissner S, t Hart BA, Herrmann H, 
Amor S. Immunization with neurofilament light protein induces spastic paresis and 
axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 2007;66:295-304. 
9. Van Noort JM, Bsibsi M, Gerritsen WH, van der Valk P, Bajramovic JJ, 
Steinman L, Amor S. Alphab-crystallin is a target for adaptive immune responses and 
a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp 
Neurol 2010;69:694-703. 
10. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
11. Amor S, Baker D, Groome N, Turk JL. Identification of a major encephalitogenic 
epitope of proteolipid protein (residues 56-70) for the induction of experimental allergic 
encephalomyelitis in Biozzi AB/H and nonobese diabetic mice. J Immunol 
1993;150:5666-72. 
12. Amor S, Groome N, Linington C, Morris MM, Dornmair K, Gardinier MV, 
Matthieu JM, Baker D. Identification of epitopes of myelin oligodendrocyte 
glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and 
Biozzi AB/H mice. J Immunol 1994;153:4349-56. 
13. Amor S, O'Neill JK, Morris MM, Smith RM, Wraith DC, Groome N, Travers PJ, 
Baker D. Encephalitogenic epitopes of myelin basic protein, proteolipid protein, myelin 
oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in 
Biozzi ABH (H-2Ag7) mice share an amino acid motif. J Immunol 1996;156:3000-8. 
14. Baker D, O'Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL. Induction 
of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J 
Neuroimmunol 1990;28:261-70. 
15. Morris-Downes MM, Smith PA, Rundle JL, Piddlesden SJ, Baker D, Pham-Dinh 
D, Heijmans N, Amor S. Pathological and regulatory effects of anti-myelin antibodies 
in experimental allergic encephalomyelitis in mice. J Neuroimmunol 2002;125:114-24. 
16. Pedotti R, Musio S, Scabeni S, Farina C, Poliani PL, Colombo E, Costanza M, 
Berzi A, Castellucci F, Ciusani E, Confalonieri P, Hemmer B, Mantegazza R, Antozzi 
C. Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of 
IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. J 
Neuroimmunol 2013;262:19-26. 
17. Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive 
multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 
2002;58:1372-81. 
18. Ehling R, Lutterotti A, Wanschitz J, Khalil M, Gneiss C, Deisenhammer F, 
Reindl M, Berger T. Increased frequencies of serum antibodies to neurofilament light 
in patients with primary chronic progressive multiple sclerosis. Mult Scler 
2004;10:601-6. 
19. Willis SN, Stathopoulos P, Chastre A, Compton SD, Hafler DA, O'Connor KC. 
Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-
Derived Immunoglobulins. Front Immunol 2015;6:600. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
20. Huizinga R, Gerritsen W, Heijmans N, Amor S. Axonal loss and gray matter 
pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 
2008;32:461-70. 
21. Krishnamoorthy G, Saxena A, Mars LT, Domingues HS, Mentele R, Ben-Nun A, 
Lassmann H, Dornmair K, Kurschus FC, Liblau RS, Wekerle H. Myelin-specific T cells 
also recognize neuronal autoantigen in a transgenic mouse model of multiple 
sclerosis. Nat Med 2009;15:626-32. 
22. Stein TD, Fedynyshyn JP, Kalil RE. Circulating autoantibodies recognize and 
bind dying neurons following injury to the brain. J Neuropathol Exp Neurol 
2002;61:1100-8. 
23. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. 
Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and 
protect against synaptic alterations. J Biol Chem 2007;282:18895-906. 
24. Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, Reif 
A, Byts N, Beck M, Jablonka S, Boettger MK, Uceyler N, Fouquet W, Gerlach M, 
Meinck HM, Siren AL, Sigrist SJ, Toyka KV, Heckmann M, Sommer C. Stiff person 
syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic 
inhibition. Brain 2010;133:3166-80. 
25. Fewou SN, Rupp A, Nickolay LE, Carrick K, Greenshields KN, Pediani J, Plomp 
JJ, Willison HJ. Anti-ganglioside antibody internalization attenuates motor nerve 
terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest 
2012;122:1037-51. 
26. Michalak Z, Lebrun A, Di Miceli M, Rousset MC, Crespel A, Coubes P, Henshall 
DC, Lerner-Natoli M, Rigau V. IgG leakage may contribute to neuronal dysfunction in 
drug-refractory epilepsies with blood-brain barrier disruption. J Neuropathol Exp 
Neurol 2012;71:826-38. 
27. Sadaba MC, Tzartos J, Paino C, Garcia-Villanueva M, Alvarez-Cermeno JC, 
Villar LM, Esiri MM. Axonal and oligodendrocyte-localized IgM and IgG deposits in MS 
lesions. J Neuroimmunol 2012;247:86-94. 
28. Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P, Giovannoni G, Baker MD, 
Baker D. Neuroprotection in a novel mouse model of multiple sclerosis. PLoS One 
2013;8:e79188. 
29. Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D. 
Practical Guide to the Mouse Induction of Relapsing Progressive Experimental 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Autoimmune Encephalomyelitis in the Biozzi ABH. Multiple Sclerosis and Related 
Disorders 2012;1:29-38. 
30. Sorensen A, Moffat K, Thomson C, Barnett SC. Astrocytes, but not olfactory 
ensheathing cells or Schwann cells, promote myelination of CNS axons in vitro. Glia 
2008;56:750-63. 
31. Boomkamp SD, Riehle MO, Wood J, Olson MF, Barnett SC. The development 
of a rat in vitro model of spinal cord injury demonstrating the additive effects of Rho 
and ROCK inhibitors on neurite outgrowth and myelination. Glia 2012;60:441-56. 
32. Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferoen-Baert R, 
Ummenthum K, Pryce G, Gerritsen W, Huizinga R, Reijerkerk A, van der Valk P, 
Baker D, Amor S. Characterization of immune response to neurofilament light in 
experimental autoimmune encephalomyelitis. J Neuroinflammation 2013;10:118. 
33. Van der Goes A, Kortekaas M, Hoekstra K, Dijkstra CD, Amor S. The role of 
anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages. J 
Neuroimmunol 1999;101:61-7. 
34. Baker D, O'Neill JK, Davison AN, Turk JL. Control of immune-mediated disease 
of the central nervous system requires the use of a neuroactive agent: elucidation by 
the action of mitoxantrone. Clin Exp Immunol 1992;90:124-8. 
35. Elliott C, Lindner M, Arthur A, Brennan K, Jarius S, Hussey J, Chan A, Stroet A, 
Olsson T, Willison H, Barnett SC, Meinl E, Linington C. Functional identification of 
pathogenic autoantibody responses in patients with multiple sclerosis. Brain 
2012;135:1819-33. 
36. Lidster K, Baker D. Optical coherence tomography detection of 
neurodegeneration in multiple sclerosis. CNS Neurol Disord Drug Targets 
2012;11:518-27. 
37. Thomson CE, Hunter AM, Griffiths IR, Edgar JM, McCulloch MC. Murine spinal 
cord explants: a model for evaluating axonal growth and myelination in vitro. J 
Neurosci Res 2006;84:1703-15. 
38. Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker 
D, Amor S, Malaspina A. Immune reactivity to neurofilament proteins in the clinical 
staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
39. Gredler V, Mader S, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer 
F, Berger T, Reindl M, Lutterotti A. Clinical and immunological follow-up of B-cell 
depleting therapy in CNS demyelinating diseases. J Neurol Sci 2013;328:77-82. 
40. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, 
Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. B-cell depletion with 
rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88. 
41. Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, Panitch H, 
Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF. Relation 
between humoral pathological changes in multiple sclerosis and response to 
therapeutic plasma exchange. Lancet 2005;366:579-82. 
42. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, 
Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma 
exchange in acute central nervous system inflammatory demyelinating disease. Ann 
Neurol 1999;46:878-86. 
43. Kaynar L, Altuntas F, Aydogdu I, Turgut B, Kocyigit I, Hacioglu SK, 
Ismailogullari S, Turgut N, Erkurt MA, Sari I, Oztekin M, Solmaz M, Eser B, Ersoy AO, 
Unal A, Cetin M. Therapeutic plasma exchange in patients with neurologic diseases: 
retrospective multicenter study. Transfus Apher Sci 2008;38:109-15. 
44. Douglas J, Gardner L, Levin M. Antibodies to an Intracellular Antigen Penetrate 
Neuronal Cells and Cause Deleterious Effects. J Clin Cell Immunol 2013;4. 
45. Magrys A, Anekonda T, Ren G, Adamus G. The role of anti-alpha-enolase 
autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J Clin Immunol 
2007;27:181-92. 
46. Qu L, Zhang P, LaMotte RH, Ma C. Neuronal Fc-gamma receptor I mediated 
excitatory effects of IgG immune complex on rat dorsal root ganglion neurons. Brain 
Behav Immun 2011;25:1399-407. 
47. Johnston KM, Brady ST, van der Kooy D, Connolly JA. A unique tubulin 
antibody which disrupts particle movement in squid axoplasm. Cell Motil Cytoskeleton 
1987;7:110-5. 
48. Brady ST, Pfister KK, Bloom GS. A monoclonal antibody against kinesin inhibits 
both anterograde and retrograde fast axonal transport in squid axoplasm. Proc Natl 
Acad Sci U S A 1990;87:1061-5. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
49. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune 
responses. Nat Rev Immunol 2008;8:34-47. 
50. Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle 
J, Giovannoni G, Baker D, Malaspina A, Puentes F. Neurofilament light antibodies in 
serum reflect response to natalizumab treatment in multiple sclerosis. Mult Scler 
2014;20:1355-62. 
 
 
Figure legends 
Figure 1. Specificity of the monoclonal antibody NF-L 10H9. (A) Western blot 
analysis illustrates the specificity of NF-L 10H9 to NF-L protein (68 kDa). Lane 1 shows 
the reactivity to spinal cord and Lane 2 the reactivity to mouse brain homogenate. (B) 
Indicates the reactivity to the recombinant NF-L protein. MW, protein standard.  
 
Figure 2. RGC density is significantly affected by NF-L 10H9. (A) RGC density and 
(B) RNFL thickness at 15 days (group A, grey bars, n = 3 mice per group, n = 2 for 
isotype control) or at 20 days (group B, black bars, n = 2 mice per group) after 
treatment with (un)labeled NF-L 10H9 or isotype control IgG1. (A) Only mice in group B 
treated with unlabeled NF-L 10H9 showed a statistically significant reduction in RGC 
density compared with mice treated with unlabeled isotype control IgG1 (Student’s t-
test, p<0.05). (B) No significant differences in percentage change in RNFL thickness 
were observed in NF-L 10H9 treated mice 15 or 20 days post-induction. 
 
Figure 3. Effect of an anti-human NF-L antibody on neuronal viability 
Differentiated PC12 cells were treated for 24h, 48h and 72h with 20 μg/ml rabbit anti-
human NF-L antibody or rabbit IgG as a control of the assay. Cells were incubated with 
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MTT (0.5 mg/ml) for the last 4 h of incubation, then supernatants were discarded and 
200 μL dimethyl sulfoxide was added to solubilise the formazan crystals. Absorbance 
was determined at 590 nm using an ELISA reader. 
 
Figure 4. mAb to NF-L reduces axonal density in rat spinal cord co-cultures. (A) 
Co-cultures were treated with NF-L 10H9 or isotype control for 0.5, 1, 2, 3, 16 or 48 h 
with 10 μg/ml mAb. Subsequently, cultures were stained for SMI310 and axonal density 
was determined using ImageJ and represented as percentage axonal loss relative to 
the isotype control IgG1.  Axonal loss was significant after 1, 2, 3, 16, or 48 h of 
treatment with NF-L 10H9 (n=4 for 0.5 and 48 h, n=3 for 1-16 h, ***p<0.0001, 
**p<0.001, *p<0.05, Student’s t-test). Representative immunofluorescent images of 
cultures treated with (B) 10 μg/ml isotype control IgG1 or (C) NF-L 10H9 for 16 h and 
stained with SMI310 (scale bars=35 μm). 
 
Supplementary Figure 1. Specificity of IgG from MS serum. IgG from pooled sera 
were selected from 16 pwMS (RRMS n=9; SPMS n=7) with high antibody levels 
reactive to NF-L using ELISA (Supplementary Table 1) in comparison to NF-L antibody 
levels in 24 healthy controls (0.79 ± 0.27 optical density). Western blotting show the 
reactivity of purified hIgG to a protein at the molecular weight of the linear NF-L protein 
(68 kDa) in mouse spinal cord (lane 1) and brain homogenates (lane 2).  
  
Supplementary Figure 2. Exacerbation of MOG35-55-induced EAE by hIgG. IgG 
from pwMS significantly exacerbated clinical neurological signs 12 to 14 days post-
immunisation compared to regular EAE mice (Mann-Whitney U test; p<0.05). On day 
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15, the animals showed a remission phase that last approximately for a week and 
afterwards the severity of disease increase again. After the peak in clinical disease, no 
statistical differences were observed between MOG35-55+ hIgG and regular EAE mice. 
Mice injected with IgG from pwMS showed a more rapid disease onset (11.8 ± 1.0) 
days versus (14.1 ± 2.1 days; p<0.05). 
 
Supplementary Figure 3. Intracerebral injection of mAb to NF-L causes transient 
neurological signs. ABH mice were injected intracerebrally with NF-L 10H9 (n=6 
mice), hIgG from pwMS (n=12 mice) or hIgG from healthy controls (n=5 mice). A and 
B) Still of a video of a mouse injected with NF-L 10H9 showed neurological signs 
including partial paralysis of hind limbs and tail stiffness. C) Video still of a mouse 
injected with hIgG from pwMS. Besides paralysis of the hind limb, mice injected with 
hIgG from pwMS showed extensive tail stiffness. D) Mouse injected with hIgG from 
healthy controls showed no signs of disease. 
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Table 2. Effect of NF-L specific anti
 
Treatment No. EAE 
Mea
s
MOG35-55 9/11 3.3
MOG35-55 + NF-L 
10H9 6/6 4.0
 
a 
mean ± SEM of maximum clinical sc
b
 mean ± SEM of maximum clinical sc
c
 mean ± SD of day of onset of clinica
d AUC ± SD Cumulative scores are exp
clinical scores were calculated as the s
**p=0.01. 
 
 
 
  
t. All rights reserved.
bodies in MOG35-55-induced EAE. 
n group 
corea 
Mean EAE 
scoreb 
Mean day of 
onsetc 
AUCd 
 ± 1.6 4.0 ± 0.0 14.1 ± 2.1 46.4 ± 1.1
 ± 0.0 4.0 ± 0.0 12.3 ± 1.0 63.2 ± 1.4
ore of EAE from all mice in the group 
ore from mice exhibiting EAE within a group 
l disease  
ressed as area under the curve (AUC). Cumulative 
um of all the daily scores over the course of EAE, 
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